Rheumatology Advance Access published online on July 16, 2003
Rheumatology, doi:10.1093/rheumatology/keg427
Rheumatology © British Society for Rheumatology 2003; all rights reserved
Original Papers
1 Centre for Rheumatology, Department of Medicine, The Middlesex Hospital, London, UK
* Corresponding author. E-mail: d.isenberg{at}ucl.ac.uk.
Received 12 December 2002
; accepted 2 May 2003
Objective. To devise new tools to assess activity and damage in patients with idiopathic inflammatory myopathies (IIM). Methods. An international multidisciplinary consensus effort to standardize the conduct and reporting of the myositis clinical trials has been established. Two tools, known as the myositis intention to treat index (MITAX) and the myositis disease activity assessment visual analogue scale (MYOACT), have been developed to capture activity in patients with IIM. In addition, the myositis damage index (MDI) has been devised to assess the extent and severity of damage developing in different organs and systems. These measures have been reviewed by the myositis experts participating in the International Myositis Assessment and Clinical Studies (IMACS) group and have been found to have good face validity and to be comprehensive. The instruments were assessed in two real patient exercises involving patients with adult dermatomyositis and inclusion body myositis. Results. The reliability of MITAX, MYOACT and MDI, measured by the intraclass correlation coefficient among the physicians, and the inter-rater reliability, as assessed by variation in the physicians' rating of patients, was fair to good for most aspects of the tools. Reliability and inter-rater agreement improved at the second exercise after the participants had completed additional training. Conclusions. The MITAX, MYOACT and MDI tools, which are now undergoing validity testing, should enhance the consistency, comprehensiveness and reliability of disease activity and damage assessment in patients with myositis.
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
2 Department of Statistical Science, University College London, UK
3 MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, UK
4 Institute of Neurology, University College London, UK
5 Rheumatology Unit, Department of Medicine, Karolinski Hospital, Karlolinska Institutet, Stockholm, Sweden
6 Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
7 Department of Paediatric and Adolescent Rheumatology, University College London, UK
8 Arthritis and Rheumatism Branch, NIAMS, Bethesda, MD, USA
9 King's College Hospital, London, UK
10 Institute of Rheumatology, Prague, Czech Republic
11 Rheumatic Diseases Centre, Hope Hospital, Salford, UK
12 Environmental Autoimmunity Group, Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Tomasova Studynkova, F. Charvat, K. Jarosova, and J. Vencovsky The role of MRI in the assessment of polymyositis and dermatomyositis Rheumatology, July 1, 2007; 46(7): 1174 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Lachenbruch, F. W. Miller, and L. G. Rider Developing international consensus on measures of improvement for patients with myositis Statistical Methods in Medical Research, February 1, 2007; 16(1): 51 - 64. [Abstract] [PDF]
|
|
|
|
 |
|
 A C Cordeiro and D A Isenberg Treatment of inflammatory myopathies. Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Ramanan, R. Schneider, M. Batthish, C. Achonu, S. Ota, M. McLimont, N. L. Young, and B. M. Feldman Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach Rheumatology, December 1, 2005; 44(12): 1574 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Isenberg, A. Rahman, E. Allen, V. Farewell, M. Akil, I. N. Bruce, D. D'Cruz, B. Griffiths, M. Khamashta, P. Maddison, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus Rheumatology, July 1, 2005; 44(7): 902 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Majithia and V. Harisdangkul Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy Rheumatology, March 1, 2005; 44(3): 386 - 389. [Abstract] [Full Text] [PDF]
|
|